Baxter reports Phase III hemophilia data for BAX 326

Baxter International Inc. (NYSE:BAX) said twice-weekly prophylactic BAX 326 met the co-primary endpoint of annualized bleed rate in the Phase III portion of an international Phase I/III trial to treat and prevent bleeding in patients over 12 years old with hemophilia B. Prophylactic BAX 326 also significantly improved physical health-related quality of life compared with baseline at six months of follow-up. Data were presented at the American Society of Hematology meeting in Atlanta. ...